Meeting
2021 Genitourinary Cancers Symposium
Prescribing patterns in patients with metastatic castrate-sensitive prostate cancer (mCSPC).
Authors
Nataliya Mar
UC Irvine Medical Center, Orange, CA
Nataliya Mar , Michael Forsyth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Cancer Disparities
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 21)
DOI
10.1200/JCO.2021.39.6_suppl.21
Abstract #
21
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).
First Author: Charles J. Ryan
Poster
2022 ASCO Genitourinary Cancers Symposium
Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).
First Author: Hirotsugu Uemura
Poster
2018 ASCO Annual Meeting
A phase II trial of enzalutamide, docetaxel and androgen deprivation therapy (ENZADA) in patients with metastatic castrate sensitive prostate cancer (mCSPC).
First Author: Earle Frederick Burgess
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay